109 related articles for article (PubMed ID: 35186767)
1. Clinical and Biological Interpretation of Survival Curves of Cancer Patients, Exemplified With Stage IV Non-Small Cell Lung Cancers With Long Follow-up.
Baak JPA; Li H; Guo H
Front Oncol; 2022; 12():837419. PubMed ID: 35186767
[TBL] [Abstract][Full Text] [Related]
2. "How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.
Guo H; Li H; Zhu L; Feng J; Huang X; Baak JPA
Front Oncol; 2021; 11():761042. PubMed ID: 34993132
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological analysis of progression-free survival (PFS) and overall survival (OS) in non-small-cell lung cancer patients in Republic of Macedonia.
Risteski M; Crvenkova S; Atanasov Z; Isjanovska R
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2013; 34(3):49-61. PubMed ID: 24566015
[TBL] [Abstract][Full Text] [Related]
4. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
6. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
7. Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.
Monnet I; Audigier-Valette C; Girard N; Vergnenègre A; Molinier O; Souquet PJ; Blanchon F; Bonnetain F; Taguieva-Pioger N; Lamour C; Wislez M
Lung Cancer; 2016 Aug; 98():84-90. PubMed ID: 27393512
[TBL] [Abstract][Full Text] [Related]
8. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
10. Clinical factors predictive of long-term survival in advanced non-small cell lung cancer.
Van Damme V; Govaerts E; Nackaerts K; Dooms C; Wauters I; Vansteenkiste J
Lung Cancer; 2013 Jan; 79(1):73-6. PubMed ID: 23083516
[TBL] [Abstract][Full Text] [Related]
11. Is there a subgroup of long-term evolution among patients with advanced lung cancer?: hints from the analysis of survival curves from cancer registry data.
Sanchez L; Lorenzo-Luaces P; Viada C; Galan Y; Ballesteros J; Crombet T; Lage A
BMC Cancer; 2014 Dec; 14():933. PubMed ID: 25496392
[TBL] [Abstract][Full Text] [Related]
12. Natural history of stage I non-small cell lung cancer: implications for early detection.
Raz DJ; Zell JA; Ou SH; Gandara DR; Anton-Culver H; Jablons DM
Chest; 2007 Jul; 132(1):193-9. PubMed ID: 17505036
[TBL] [Abstract][Full Text] [Related]
13. [The value of neuroendocrine markers for response to therapy and survival in patients with advanced non-small cell lung cancer].
Petrović M; Ilić N; Baskić D
Srp Arh Celok Lek; 2010; 138(1-2):37-42. PubMed ID: 20422910
[TBL] [Abstract][Full Text] [Related]
14. Screening and staging for non-small cell lung cancer by serum laser Raman spectroscopy.
Wang H; Zhang S; Wan L; Sun H; Tan J; Su Q
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Aug; 201():34-38. PubMed ID: 29729529
[TBL] [Abstract][Full Text] [Related]
15. Potential Influence on Clinical Trials of Long-Term Survivors of Stage IV Non-small cell Lung Cancer.
Davis JS; Prophet E; Peng HL; Lee HY; Tidwell RSS; Lee JJ; Thomas A; Szabo E; Chang S
JNCI Cancer Spectr; 2019 Jun; 3(2):pkz010. PubMed ID: 31218274
[TBL] [Abstract][Full Text] [Related]
16. Mammography screening: A major issue in medicine.
Autier P; Boniol M
Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
[TBL] [Abstract][Full Text] [Related]
17. [Prognosis after complete surgical resection for non-small cell lung cancer based on the staging classification].
Pfannschmidt J; Muley T; Hoffmann H; Bülzebruck H; Dienemann H
Dtsch Med Wochenschr; 2006 Nov; 131(47):2643-8. PubMed ID: 17109272
[TBL] [Abstract][Full Text] [Related]
18. Second primary tumors involving non-small cell lung cancer: prevalence and its influence on survival.
Duchateau CS; Stokkel MP
Chest; 2005 Apr; 127(4):1152-8. PubMed ID: 15821189
[TBL] [Abstract][Full Text] [Related]
19. Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.
Aoki T; Akiba T; Nishiyama J; Tajiri S; Hayama N; Takahashi G; Tanaka J; Sato M; Takiguchi H; Tomomatsu H; Tomomatsu K; Takihara T; Niimi K; Oguma T; Kohno M; Masuda R; Urano T; Itoh H; Kajiwara H; Nakamura N; Kunieda E; Matsumae M; Iwazaki M; Asano K
Respir Res; 2019 Nov; 20(1):263. PubMed ID: 31752884
[TBL] [Abstract][Full Text] [Related]
20. A genetic sequence variant (GSV) at susceptibility loci of 5p15.33 (TERT-CLPTM1L) is associated with survival outcome in locally advanced and metastatic non-small-cell lung cancer (NSCLC).
Azad AK; Qiu X; Boyd K; Kuang Q; Emami M; Perera N; Palepu P; Patel D; Chen Z; Cheng D; Feld R; Leighl NB; Shepherd FA; Tsao MS; Xu W; Liu G; Cuffe S
Lung Cancer; 2014 Jun; 84(3):289-94. PubMed ID: 24679952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
